Immodulon, Pioneers in Immuno-oncology
“Our Mission is to improve the lives of patients suffering from life-threatening cancers through novel therapies that boost their immune response and improve the performance of their cancer treatment, enabling them to live happier, healthier and longer lives.”
Pipeline
Immodulon is dedicated to developing novel, safe and effective immunotherapy treatments for cancer patients. We believe that our lead candidate, the immunomodulator IMM-101, will become the backbone therapy across multiple tumour types in combination with any of the four major pillars of cancer therapy: immunotherapy, chemotherapy, radio/ablation therapy and surgery.
IMM-101 is being investigated in a broad clinical programme, these are either Immodulon Sponsored, or Investigator Sponsored Studies.
- ADVANCED PANCREATIC CANCER (PHASE II)
- ADVANCED MELANOMA (PHASE I/II)
- COLORECTAL CANCER (PHASE I/II)
- SARCOMA (PHASE I/II)
- COVID-19 (PHASE III)
IMM-101 and COVID-19
IMM-101, having demonstrated the ability to induce innate immune responses in cancer patients, is being evaluated in a Phase III clinical trial for COVID-19 in cancer patients.
Latest from Immodulon
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center Erasmus MC initiates recruitment for new investigator-sponsored phase I/II study to investigate the safety and efficacy of...
Immodulon to present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event on clinical biomarkerstrategies with complex immunomodulators
Presentation on circulatory immunological biomarkers in cancer patients and novel technologies during clinical trials Uxbridge, UK – 15 March 2021 – Immodulon, the immuno-oncology company, announces that its Chief Scientific Officer, Dr. Thomas Kleen, will present at...
Immodulon announces Notices of Allowance and Intention to Grant for four patent applications related to IMM-101 in combination with immune checkpoint inhibitors in US, Japan and Europe
Claims cover methods of treating cancer with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies Uxbridge, UK, 8 March 2021 – Immodulon, the immuno-oncology company, today announced that it has received Notices of Allowance from the U.S. Patent...